BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors

PALO ALTO, Calif. – June 24, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added three new independent directors to its board: former Allergan CEO and biopharma deal-maker, Brent Saunders; genomics pioneer and entrepreneur, Randy Scott, Ph.D.; and renowned economist and BridgeBio co-founder, […]

BridgeBio Pharma, Inc. and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases

Partnership to Leverage University of Florida’s Research in Gene Therapy and BridgeBio’s Translational Expertise in Rare and Genetic Disease PALO ALTO, Calif. – June 18, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, has entered into a strategic collaboration with the University of Florida to translate research in […]

BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases

PALO ALTO, Calif. – June 18, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has entered into a collaboration agreement with Johns Hopkins University to support the translation of academic innovations in genetically driven diseases with a goal of clinical development and potential commercialization […]

BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

ML Bio Solutions has initiated a Phase 1 clinical trial of BBP-418 in healthy volunteers ML Bio Solutions’ sponsored lead-in study is enrolling patients with LGMD2i across twelve sites in the U.S. and internationally, in collaboration with the LGMD-GRASP consortium SAN FRANCISCO, CA– June 11, 2020— BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate ML Bio Solutions […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., June 5, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on June 1, 2020, the compensation committee of BridgeBio’s board of directors granted nine employees options to purchase an aggregate of 55,517 shares of the Company’s common stock with a per share […]